Literature DB >> 18424331

From infectious diseases to primary immunodeficiencies.

Jacinta Bustamante1, Shen-Ying Zhang, Horst von Bernuth, Laurent Abel, Jean-Laurent Casanova.   

Abstract

The field of primary immunodeficiencies has expanded, thanks to the exploration of novel clinical phenotypes and their connection with morbid genotypes, and the subsequent exploration of new patients who have known primary immunodeficiency-defining clinical phenotypes and their connection with novel morbid genotypes. This two-way process is becoming increasingly active, particularly for patients who have infectious diseases in whom the underlying immunologic and genetic causes remain mostly unexplained. The authors review how the exploration of children who have clinical infectious diseases caused by mycobacteria, pneumococcus, and herpes simplex virus recently led to the description of three new groups of primary immunodeficiencies. These three examples justify the continuation of the genetic exploration of novel infectious phenotypes and novel patients who have infections. This challenging process will eventually reap its rewards, to the benefit of patients and their families.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18424331     DOI: 10.1016/j.iac.2008.01.009

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  10 in total

Review 1.  Adult-onset presentations of genetic immunodeficiencies: genes can throw slow curves.

Authors:  Katharine S Nelson; David B Lewis
Journal:  Curr Opin Infect Dis       Date:  2010-08       Impact factor: 4.915

Review 2.  Pneumococcal vaccine and patients with pulmonary diseases.

Authors:  Mehdi Mirsaeidi; Golnaz Ebrahimi; Mary Beth Allen; Stefano Aliberti
Journal:  Am J Med       Date:  2014-05-20       Impact factor: 4.965

Review 3.  Mechanisms of Bacterial Colonization of the Respiratory Tract.

Authors:  Steven J Siegel; Jeffrey N Weiser
Journal:  Annu Rev Microbiol       Date:  2015       Impact factor: 15.500

Review 4.  Innate defects of the IL-12/IFN-γ axis in susceptibility to infections by mycobacteria and salmonella.

Authors:  Noé Ramirez-Alejo; Leopoldo Santos-Argumedo
Journal:  J Interferon Cytokine Res       Date:  2013-12-20       Impact factor: 2.607

5.  Combined immunodeficiency associated with DOCK8 mutations.

Authors:  Qian Zhang; Jeremiah C Davis; Ian T Lamborn; Alexandra F Freeman; Huie Jing; Amanda J Favreau; Helen F Matthews; Joie Davis; Maria L Turner; Gulbu Uzel; Steven M Holland; Helen C Su
Journal:  N Engl J Med       Date:  2009-09-23       Impact factor: 91.245

6.  Refractory disseminated coccidioidomycosis and mycobacteriosis in interferon-gamma receptor 1 deficiency.

Authors:  Donald C Vinh; Fares Masannat; Robert B Dzioba; John N Galgiani; Steven M Holland
Journal:  Clin Infect Dis       Date:  2009-09-15       Impact factor: 9.079

7.  Identification of a chemical that inhibits the mycobacterial UvrABC complex in nucleotide excision repair.

Authors:  Nayef Mazloum; Melanie A Stegman; Deborah L Croteau; Bennett Van Houten; Nyoun Soo Kwon; Yan Ling; Caitlyn Dickinson; Aditya Venugopal; Mohammad Atif Towheed; Carl Nathan
Journal:  Biochemistry       Date:  2011-01-31       Impact factor: 3.162

Review 8.  Mouse ENU Mutagenesis to Understand Immunity to Infection: Methods, Selected Examples, and Perspectives.

Authors:  Grégory Caignard; Megan M Eva; Rebekah van Bruggen; Robert Eveleigh; Guillaume Bourque; Danielle Malo; Philippe Gros; Silvia M Vidal
Journal:  Genes (Basel)       Date:  2014-09-29       Impact factor: 4.096

9.  Bacille Calmette-Guérin vaccination in Saudi Arabia: benefits versus risks.

Authors:  Suliman Al Jumaah; Sami Al Hajjar; Hamoud Al Mousa
Journal:  Ann Saudi Med       Date:  2012 Jan-Feb       Impact factor: 1.526

10.  Suppression of hepcidin expression and iron overload mediate Salmonella susceptibility in ankyrin 1 ENU-induced mutant.

Authors:  Kyoko E Yuki; Megan M Eva; Etienne Richer; Dudley Chung; Marilène Paquet; Mathieu Cellier; François Canonne-Hergaux; Sophie Vaulont; Silvia M Vidal; Danielle Malo
Journal:  PLoS One       Date:  2013-02-04       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.